MediSpectra Cervical Imaging System Gains FDA Panel Review
This article was originally published in The Gray Sheet
Executive Summary
FDA's Obstetrics & Gynecology Devices Panel will meet on May 17 to review data from a 13-site, 2,200-woman trial for MediSpectra's Luma spectroscopy-based cervical imaging system